The Dopamine Hypothesis of Schizophrenia: An Historical and Philosophical Analysis

The dopamine (DA) hypothesis of schizophrenia (DHS) has, since its inception over 30 years ago, been among the most prominent etiologic theories in psychiatry. This essay begins by summarizing the history of its emergence and efforts to empirically test it through the examination of (i) cerebrospinal fluid DA metabolites, (ii) neuroendocrine measures, (iii) clinical response to psychostimulants, (iv) brain levels of DA and its metabolites, (v) brain studies of DA receptors, and (vi) genetic association studies. We then examine how successful the DHS has been and by what criteria its performance should be evaluated. In this process, it is critical to distinguish the etiological DHS from the pharmacological DA hypothesis of neuroleptic action. Although the DHS stimulated much science, most efforts to empirically validate it have failed, in contrast with the well-supported pharmacological DA hypothesis of neuroleptic action. Nonetheless, the DHS has held the status of a scientific paradigm defended by some with great avidity. Like other temporally extended theories, the DHS in its most general form is relatively nonspecific and protean in nature. In its evolution through successive more specific forms, often embodying ad hoc modifications of subsidiary hypotheses, it became very difficult to falsify. Although stimulating much research, it has not produced a progressive research program generating various novel and confirmed predictions about schizophrenia. For most of its history, the DHS has lacked a viable competing alternative theory against which it could be incisively compared. Sociological factors, especially the rise to prominence of the biological psychiatry movement, and the conflation of the DHS and the DA theory of antipsychotic drug action have probably played an important role in its persistence. Psychiatry needs theories with higher levels of specificity and falsifiability. As the science of psychiatry matures, the field needs to become more self-critical about the validity of its theories.

[1]  Montagu Ka Catechol Compounds in Rat Tissues and in Brains of Different Animals , 1957 .

[2]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[3]  R. V. Van Heertum,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Laudan Progress and Its Problems , 1977 .

[5]  J. Platt Strong Inference: Certain systematic methods of scientific thinking may produce much more rapid progress than others. , 1964, Science.

[6]  S. Stahl,et al.  The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.

[7]  K. Fuxe,et al.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. , 1964, Acta physiologica Scandinavica. Supplementum.

[8]  H. Chaiklin Blaming the Brain: The Truth About Drugs and Mental Health. , 2000 .

[9]  T. Broadbent,et al.  Criticism and the Growth of Knowledge , 1972 .

[10]  P. Willner The dopamine hypothesis of schizophrenia: current status, future prospects. , 1997, International clinical psychopharmacology.

[11]  K. Popper,et al.  Conjectures and Refutations , 1963 .

[12]  S. Snyder,et al.  The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. , 1976, The American journal of psychiatry.

[13]  J. Hietala,et al.  Dopamine in schizophrenia. , 1996, Annals of medicine.

[14]  C. Rădulescu,et al.  Pink Spot as a Diagnostic Test in Schizophrenia , 1968, Nature.

[15]  A. Serretti,et al.  VNTR Polymorphism of Tyrosine Hydroxylase Gene and Schizophrenia in the Korean Population , 2003, Neuropsychobiology.

[16]  B. Bunney,et al.  Dopamine “Autoreceptors”: Pharmacological characterization by microiontophoretic single cell recording studies , 1977, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  G. Kirov,et al.  No association between schizophrenia and polymorphisms in COMT in two large samples. , 2005, The American journal of psychiatry.

[18]  E. Pinto,et al.  [Psychostimulants]. , 1968, Revue medicale de Liege.

[19]  J. Francis,et al.  Historical Development of the Dopamine Hypothesis of Schizophrenia , 2002, Journal of the history of the neurosciences.

[20]  Philip Kitcher,et al.  Precis of The Advancement of Science@@@The Advancement of Science: Science without Legend, Objectivity without Illusions. , 1995 .

[21]  O. Johansson,et al.  Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia , 1974, Science.

[22]  T. C. Chamberlin The Method of Multiple Working Hypotheses , 1931, The Journal of Geology.

[23]  Michael A. Schwartz,et al.  Philosophical Perspectives On Psychiatric Diagnostic Classification , 1994 .

[24]  R. Tandon Schizophrenia and other psychotic disorders in DSM-5. , 2013, Clinical schizophrenia & related psychoses.

[25]  E. Jönsson,et al.  The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: Evidence from fixed‐ and random‐effects meta‐analyses , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[26]  P. Thagard,et al.  How Scientists Explain Disease , 1999 .

[27]  M. Hampson,et al.  Dopa decarboxylase genotypes may influence age at onset of schizophrenia , 2001, Molecular Psychiatry.

[28]  T. Sourkes On the origin of homovanillic acid (HVA) in the cerebrospinal fluid , 2005, Journal of Neural Transmission.

[29]  A. Carlsson,et al.  A half-century of neurotransmitter research: impact on neurology and psychiatry , 2002, European Psychiatry.

[30]  S. Snyder,et al.  Prospects for research on schizophrenia. V. Pharmacological observations, Drug-induced psychoses. , 1972, Neurosciences Research Program bulletin.

[31]  Peter Urbach,et al.  Scientific Reasoning: The Bayesian Approach , 1989 .

[32]  Yan Shen,et al.  No association between polymorphisms in the DDC gene and paranoid schizophrenia in a northern Chinese population , 2004, Psychiatric genetics.

[33]  J. Platt Strong Inference , 2007 .

[34]  I. Lakatos Falsification and the Methodology of Scientific Research Programmes , 1976 .

[35]  M. Kendall,et al.  The Logic of Scientific Discovery. , 1959 .

[36]  Karl R. Popper The Logic of Scientific Discovery. , 1977 .

[37]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  S. Kety H. CATECHOLAMINES IN NEUROPSYCHIATRIC STATES , 1966 .

[39]  M. Vichnar,et al.  [Borderline personality disorder]. , 1992, Ceskoslovenska pediatrie.

[40]  N. Andreasen Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS) 1982 , 2007 .

[41]  O Hornykiewicz,et al.  Dopamine in thelimbic regions of the human brain: normal and abnormal. , 1977, Advances in biochemical psychopharmacology.

[42]  G L Ada,et al.  The clonal-selection theory. , 1987, Scientific American.

[43]  S. Faraone,et al.  Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene , 2005, Schizophrenia Research.

[44]  Dudley Shapere Reason and the search for knowledge : investigations in the philosophy of science , 1984 .

[45]  T. Terao,et al.  Dopamine D1 receptor gene polymorphism and schizophrenia in Japan. , 1999, American journal of medical genetics.

[46]  T. Hökfelt,et al.  A fluorescence and electron microscopic study on central monoamine nerve cells , 1966, The Anatomical record.

[47]  P. Kitcher The Advancement of Science , 1993 .

[48]  Kenneth S Kendler,et al.  Toward a philosophical structure for psychiatry. , 2005, The American journal of psychiatry.

[49]  O. Saitoh,et al.  Differential Effects of Mental Stress on Plasma Homovanillic Acid in Schizophrenia and Normal Controls , 1999, Neuropsychopharmacology.

[50]  H. Tuckwell,et al.  A meta-analysis of homovanillic acid concentrations in schizophrenia. , 1993, The International journal of neuroscience.

[51]  K. Davis,et al.  The effects of diet and physical activity on plasma homovanillic acid in normal human subjects , 1983, Psychiatry Research.

[52]  F. Oyebode,et al.  Philosophical Issues in Psychiatry: Explanation, Phenomenology and Nosology , 2010, British Journal of Psychiatry.

[53]  J. Rothwell Principles of Neural Science , 1982 .

[54]  C. Billington,et al.  A review of GHRH stimulation test in psychiatry , 1994, Biological Psychiatry.

[55]  S H Snyder,et al.  Drugs, neurotransmitters, and schizophrenia. , 1974, Science.

[56]  S. Cichon,et al.  Dopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analyses , 2003, Schizophrenia Research.

[57]  H. K. Lee,et al.  The antagonism of amphetamine-induced symptomatology by a neuroleptic. , 1974, The American journal of psychiatry.

[58]  I. Kopin Parkinson's Disease: Past, Present, and Future , 1993, Neuropsychopharmacology.

[59]  Paul William Preu,et al.  Theory and Practice of Psychiatry , 1936, The Yale Journal of Biology and Medicine.

[60]  E. Mignot,et al.  Free and conjugated plasma homovanillic acid in schizophrenic patients , 1989, Biological Psychiatry.

[61]  J. M. Schneck A history of psychiatry , 1960 .

[62]  T. M. Brown The College of Physicians and the acceptance of iatromechanism in England, 1665-1695. , 1970, Bulletin of the history of medicine.

[63]  T. Kuhn,et al.  The Structure of Scientific Revolutions , 1963 .

[64]  R. Sinke,et al.  No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[65]  M. Talkowski,et al.  Dopamine genes and schizophrenia: case closed or evidence pending? , 2007, Schizophrenia bulletin.

[66]  G. Thieme,et al.  FLUORESCENCE OF CATECHOL AMINES AND RELATED COMPOUNDS CONDENSED WITH FORMALDEHYDE , 1962 .

[67]  S. Matthysse,et al.  Biochemical aspects of schizophrenia. , 1975, Annual review of medicine.

[68]  J. Beckmann,et al.  A highly significant association between a COMT haplotype and schizophrenia. , 2002, American journal of human genetics.

[69]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[70]  G. Reynolds,et al.  Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex. , 2001, Journal of psychiatric research.

[71]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[72]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[73]  M. Munafo,et al.  Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case–control studies , 2005, Molecular Psychiatry.

[74]  P. Sullivan,et al.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. , 2003, Archives of general psychiatry.

[75]  R. Kahn,et al.  Assessment of the central dopaminergic index of plasma HVA in schizophrenia. , 1995, Schizophrenia bulletin.

[76]  L. W. Thompson The dopamine hypothesis of schizophrenia. , 2009, Perspectives in psychiatric care.

[77]  The molecular genetics of schizophrenia. , 1996 .

[78]  Susan R. George,et al.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.

[79]  W. Wilson,et al.  A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia , 1996, Biological Psychiatry.

[80]  K. Montagu Catechol Compounds in Rat Tissues and in Brains of Different Animals , 1957, Nature.

[81]  W. Livesley The DSM-IV personality disorders. , 1995 .

[82]  R. Gur,et al.  Prognostic variables at intake and long-term level of function in schizophrenia. , 2006, The American journal of psychiatry.

[83]  Astrophysical Observations: Lensing and Eclipsing Einstein's Theories , 2005, Science.

[84]  M. Gazzaniga The cognitive neurosciences, 3rd edition , 2004 .

[85]  E. Walker,et al.  Dopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings , 2001, Behavioural pharmacology.

[86]  Lin He,et al.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis , 2005, Biological Psychiatry.

[87]  I. Glick,et al.  Schizophrenia and Other Psychotic Disorders , 2004 .

[88]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[89]  J. Lacasse,et al.  Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature , 2005, PLoS medicine.

[90]  Edward Shorter,et al.  A History of Psychiatry: From the Era of the Asylum to the Age of Prozac , 1996 .

[91]  J. Lieberman,et al.  Psychoneuroendocrinology of schizophrenia. , 1998, The Psychiatric clinics of North America.

[92]  T. Kuhn The structure of scientific revolutions, 3rd ed. , 1996 .

[93]  Alan A. Wilson,et al.  Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with11C-N-methylspiperone , 1993, Psychiatry Research.

[94]  S. Schultz Principles of Neural Science, 4th ed. , 2001 .

[95]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[96]  S. Matthysse Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? , 1973, Federation proceedings.

[97]  A. Carlsson Does dopamine have a role in schizophrenia? , 1978, Biological psychiatry.

[98]  J. Caplehorn,et al.  Amphetamine psychosis. , 1990, British journal of addiction.

[99]  A. Faurbye The role of amines in the etiology of schizophrenia. , 1968, Comprehensive psychiatry.

[100]  Sir Bernard Katz Planning and following the unexpected in scientific research , 1994 .

[101]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[102]  J. Dorling,et al.  Bayesian personalism, the methodology of scientific research programmes, and Duhem's problem , 1979 .

[103]  J. Peto,et al.  Molecular pathology of schizophrenia: more than one disease process? , 1980 .

[104]  U. Ungerstedt,et al.  ASCENDING SYSTEMS OF CATECHOLAMINE NEURONS FROM THE LOWER BRAIN STEM. , 1964, Acta physiologica Scandinavica.

[105]  T. C. Chamberlin The Method of Multiple Working Hypotheses: With this method the dangers of parental affection for a favorite theory can be circumvented. , 1965, Science.

[106]  F. Moeller,et al.  Serum homovanillic acid levels in schizophrenic patients and normal control subjects , 1993, Psychiatry Research.

[107]  S. Lal,et al.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? , 2001, Journal of psychiatry & neuroscience : JPN.

[108]  G. Pearlson,et al.  Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. , 1993, Psychiatry research.

[109]  L. Wolpert Popper , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[110]  P. Kitcher,et al.  The advancement of science : science without legend, objectivity without illusions , 1995 .

[111]  Anissa Abi-Dargham,et al.  Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.

[112]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[113]  N. Foster,et al.  Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. , 1986, Archives of general psychiatry.

[114]  E. Bizzi,et al.  The Cognitive Neurosciences , 1996 .

[115]  R. Kaiser,et al.  Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia , 2004, Psychiatric genetics.

[116]  Alexander L. Miller,et al.  Studies of Catecholamine Metabolism in Schizophrenia/Psychosis-I , 1993, Neuropsychopharmacology.

[117]  D. Grandy,et al.  Cloning and expression of a rat D2 dopamine receptor cDNA , 1988, Nature.

[118]  D. Jeste,et al.  Low dose bromocriptine: A study of acute effects in chronic medicated schizophrenics , 1984, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[119]  K. Schaffner Discovery and Explanation in Biology and Medicine , 1994 .

[120]  S. Kety Catecholamines in neuropsychiatric states. , 1966, Pharmacological reviews.

[121]  Glenn Shafer,et al.  Scientific Reasoning: The Bayesian Approach (3rd ed.), Colin Howson and Peter Urbach , 2007 .

[122]  J. Lieberman,et al.  Provocative tests with psychostimulant drugs in schizophrenia , 2004, Psychopharmacology.

[123]  I. Lakatos,et al.  Criticism and the Growth of Knowledge: Falsification and the Methodology of Scientific Research Programmes , 1970 .

[124]  S. Kety BIOCHEMICAL THEORIES OF SCHIZOPHRENIA. , 1965, International journal of psychiatry.

[125]  S. Faraone,et al.  DRD2 −141C insertion/deletion polymorphism is not associated with schizophrenia: Results of a meta‐analysis , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[126]  G. Pearlson,et al.  Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[127]  J. Csernansky,et al.  Are there neurochemical indicators of risk for schizophrenia? , 1994, Schizophrenia bulletin.